Sign in

HOWL on Nasdaq

Werewolf Therapeutics, Inc.

In its 2026 annual report the company says: “We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies.”3 It is headquartered in Waltham, Massachusetts.1 Its shares trade on Nasdaq under the symbol HOWL.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerHOWL on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWaltham, Massachusetts1
  • Incorporated inDE2
  • Business address303 Wyman Street, Suite 300, Waltham, Ma 024512
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to as INDUKINE and INDUCER molecules, are intended to activate selectively in the tumor microenvironment, or TME. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12), respectively, INDUKINE molecules for the treatment of multiple tumor types.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$60.7M in 2025+171% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$22.4M-$22.4M20202021: -$50.1M-$50.1M2021+124%2022: -$56.1M-$56.1M2022+12%2023: -$40.5M-$40.5M2023−28%2024: -$73.6M-$73.6M2024+82%2025: -$60.7M-$60.7M2025−18%
Net income45678-$60.8M in 2025+304% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$15.0M-$15.0M20202021: -$50.0M-$50.0M2021+232%2022: -$53.8M-$53.8M2022+8%2023: -$37.4M-$37.4M2023−31%2024: -$70.5M-$70.5M2024+89%2025: -$60.8M-$60.8M2025−14%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Collaboration revenue$0$1.9M
Research and development$44.8M$56.4M
General and administrative$15.8M$19.0M
Total operating expenses$60.7M$75.5M
Operating loss-$60.7M-$73.6M
Interest income$3.1M$6.7M
Interest expense-$5.3M-$4.7M
Loss on extinguishment of debt$0-$553.0K
Other income, net$2.0M$1.6M
Total other (expense) income-$145.0K$3.1M
Net loss-$60.8M-$70.5M
Net loss per common share, basic (in usd per share)-$1.32-$1.63
Net loss per common share, diluted (in usd per share)-$1.33-$1.63
Weighted average common shares outstanding, basic (in shares)46.0M shares43.3M shares
Weighted average common shares outstanding, diluted (in shares)46.8M shares43.9M shares

Compare Werewolf Therapeutics, Inc. with another company

Corporate structure

Werewolf Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Werewolf Therapeutics, Inc.

  • Werewolf Therapeutics, Inc. Waltham, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Werewolf Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$11.3M8 Dec 31, 2025$11.3M8 Dec 31, 20240%
Property and equipment, net$4.7M8 Dec 31, 2025$6.3M8 Dec 31, 2024−25.8%
Operating-lease assets (leased space)$5.2M8 Dec 31, 2025$6.0M8 Dec 31, 2024−13.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$57.0M8 Dec 31, 2025$111.0M8 Dec 31, 2024−48.6%

Properties, in its own words

Our principal facilities consist of office and laboratory space. We currently occupy 25,778 square feet of office and laboratory space in Watertown, Massachusetts under a lease that expires in May 2030. We believe that our existing facilities will be adequate and suitable for our needs for the foreseeable future.

Item 2 of the 10-K filed Mar 27, 2026.3

Leadership

Who has led Werewolf Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Timothy W. Trost2021–now

Chief operating officer

  1. Reid Leonard2021–2023
2025
Board members and other officers (17)

Timeline

  1. Aug 21, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure28
  2. Aug 20, 20268-K Entered a material agreement29
  3. Jul 31, 20268-K Results of operations30
  4. May 7, 20268-K Results of operations31
  5. Mar 27, 20268-K Results of operations32
  6. Feb 24, 20268-K Other events33
  7. Feb 13, 20268-K Exit or restructuring costs; Executive or director change; Regulation FD disclosure34
  8. Feb 6, 20268-K Listing notice or transfer35
  9. Dec 18, 20258-K Other events36
  10. Nov 4, 20258-K Results of operations37
  11. Oct 6, 20258-K Listing notice or transfer38
  12. Aug 14, 20258-K Results of operations; Regulation FD disclosure39

Calendar

Coming up

  1. Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.36) a share, on Nov 4, 2025.40

When it reported results

  1. Jul 31, 2026Reported quarterly or annual results30
  2. May 7, 2026Reported quarterly or annual results31
  3. Mar 27, 2026Reported quarterly or annual results32
  4. Nov 4, 2025Reported quarterly or annual results37
  5. Aug 14, 2025Reported quarterly or annual results39
  6. May 8, 2025Reported quarterly or annual results41
  7. Mar 11, 2025Reported quarterly or annual results42
  8. Nov 7, 2024Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

369 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 47 major events, 124 insider forms, 35 large holders, 143 other. The latest 20:

  1. Sep 22, 2026S-4 EDGAR
  2. Sep 21, 2026SCHEDULE 13G EDGAR
  3. Aug 21, 2026425 EDGAR
  4. Aug 21, 20268-K EDGAR
  5. Aug 20, 20268-K EDGAR
  6. Jul 31, 202610-Q EDGAR
  7. Jul 31, 20268-K EDGAR
  8. Jul 8, 20264 EDGAR
  9. Jul 6, 2026144 EDGAR
  10. Jul 6, 2026144 EDGAR
  11. Jul 6, 2026144 EDGAR
  12. Jul 6, 2026144 EDGAR
  13. Jul 6, 2026144 EDGAR
  14. Jul 6, 2026144 EDGAR
  15. Jul 2, 2026SCHEDULE 13D/A EDGAR
  16. Jun 29, 2026144 EDGAR
  17. Jun 29, 2026144 EDGAR
  18. Jun 29, 2026144 EDGAR
  19. Jun 29, 2026144 EDGAR
  20. Jun 29, 2026144 EDGAR

The 369 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

161 open-market trades by officers, directors and large owners since October 2021: 4 buys and 157 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 7, 2026EVNIN LUKEDirectorSale107,429$0.31$33.3KForm 4
Jul 6, 2026EVNIN LUKEDirectorSale35,770$0.32$11.4KForm 4
Jun 29, 2026EVNIN LUKEDirectorSale157,084$0.30$47.1KForm 4
Jun 17, 2026RA CAPITAL MANAGEMENT, L.P.10% ownerSale416,911$0.35$145.9KForm 4
Jun 16, 2026RA CAPITAL MANAGEMENT, L.P.10% ownerSale149,625$0.37$55.4KForm 4
Jun 15, 2026RA CAPITAL MANAGEMENT, L.P.10% ownerSale128,770$0.39$50.2KForm 4
Jun 12, 2026RA CAPITAL MANAGEMENT, L.P.10% ownerSale170,441$0.40$68.2KForm 4
Jun 11, 2026Kolchinsky Peter10% ownerSale262,503$0.38$99.8KForm 4
Jun 10, 2026Kolchinsky Peter10% ownerSale45,923$0.37$17.0KForm 4
Jun 9, 2026Kolchinsky Peter10% ownerSale369,800$0.37$136.8KForm 4
Jun 9, 2026EVNIN LUKEDirectorSale76,928$0.37$28.5KForm 4
Jun 8, 2026EVNIN LUKEDirectorSale60,547$0.40$24.2KForm 4
Jun 5, 2026EVNIN LUKEDirectorSale24,946$0.40$10.0KForm 4
Jun 4, 2026EVNIN LUKEDirectorSale20,072$0.44$8.8KForm 4
Jun 3, 2026EVNIN LUKEDirectorSale29,749$0.42$12.5KForm 4
Jun 2, 2026EVNIN LUKEDirectorSale29,595$0.45$13.3KForm 4
Jun 1, 2026EVNIN LUKEDirectorSale80,459$0.47$37.8KForm 4
May 29, 2026EVNIN LUKEDirectorSale32,556$0.45$14.7KForm 4
May 28, 2026EVNIN LUKEDirectorSale27,698$0.46$12.7KForm 4
May 27, 2026EVNIN LUKEDirectorSale80,852$0.48$38.8KForm 4

All 161 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Daniel J. Hicklin, Ph.D.President and Chief Executive Officer62$608.2K$2.5M54
2024Randi Isaacs, M.D.Chief Medical Officer69$494.1K$1.4M54
2024Timothy W. TrostChief Financial Officer and Treasurer67$466.0K$1.2M54
2023Daniel J. Hicklin, Ph.D.President and Chief Executive Officer62$583.4K$1.4M54
2023Randi Isaacs, M.D.Chief Medical Officer69$474.0K$855.8K54
2023Timothy W. TrostChief Financial Officer and Treasurer67$447.0K$815.6K54

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 45. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ra Capital Management, L.P.2,387,744$859.3K0.0%−4,293,563
Balyasny Asset Management L.P.1,790,089$644.3K0.0%New
Vanguard Capital Management LLC1,217,976$438.5K0.0%No change
Renaissance Technologies LLC674,632$242.8K0.0%+158,414
Lynx1 Capital Management LP657,786$236.7K0.0%No change
Sphera Funds Management Ltd.626,810$225.6K0.0%No change
DC Funds, LP589,102$212.0K16.9%No change
Verdad Advisers, LP348,709$125.5K0.1%+318,949
Geode Capital Management, LLC335,815$120.9K0.0%−53,672
Bank Of America Corp /de/311,502$111.8K0.0%+46,919
XTX Topco Ltd271,478$97.7K0.0%+220,549
Jane Street Group, LLC251,837$90.6K0.0%+169,001
UBS Group AG215,838$77.7K0.0%+148,981
Vanguard Fiduciary Trust Co157,726$56.8K0.0%No change
State Street Corp119,168$42.9K0.0%No change
Squarepoint Ops LLC103,242$37.2K0.0%New
BlackRock, Inc.101,573$36.6K0.0%−35
Rangeley Capital, LLC100,000$36.0K0.0%New
Northern Trust Corp86,851$31.3K0.0%No change
Alyeska Investment Group, L.P.86,554$31.2K0.0%No change
Mpm Bioimpact LLC80,142$28.9K0.0%−1,128,668
Millennium Management LLC62,055$22.3K0.0%−69,995
Two Sigma Investments, LP27,300$9.8K0.0%New
StoneX Group Inc.20,000$9.0K0.0%New
Goldman Sachs Group Inc20,023$7.2K0.0%−18,243

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Werewolf Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARWerewolf Therapeutics, Inc.1
  • CIK0001785530
  • Employer ID (EIN)82-35231803
  • Filer statusNon‑accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address303 Wyman Street, Suite 300, Waltham, MA 024511
  • Phone617-952-05551
  • Shares outstanding48,599,066 as of Jul 27, 202610
  • Public float$39.6M as of Jun 30, 20253
  • AuditorErnst & Young LLP, Boston, Massachusetts PCAOB ID 42; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceAug 15, 20191
  • Filings449 in all: 4 (144), 144 (114), 8-K (52), 3 (28), 10-Q (17), SCHEDULE 13D/A (14), SC 13G/A (8), SC 13G (7)1
    All 35 form types

    S-8 (6), 10-K (5), CORRESP (5), SC 13D/A (5), DEF 14A (4), DEFA14A (4), SC 13D (4), ARS (3), EFFECT (3), SCHEDULE 13G/A (3), UPLOAD (3), 424B5 (2), D (2), S-3 (2), SEC STAFF LETTER (2), 424B4 (1), 425 (1), 8-A12B (1), CERT (1), D/A (1), DRS (1), S-1 (1), S-1/A (1), S-1MEF (1), S-4 (1), S-8 POS (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2026
    Quarterly report (10-Q) Jul 31, 2026
    Proxy statement (DEF 14A) Apr 28, 2025
    Latest 8-K (8-K) Aug 21, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par value per shareHOWLThe Nasdaq Global Select Market

From the cover page of the 10-K filed Mar 27, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Werewolf Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 27, 2026: 77 risks under these headings, as written.3

  • Risks Related to Our Limited Operating History, Financial Position and Capital Requirements
  • Substantial doubt exists as to our ability to continue as a going concern.
  • We will need additional funding. If we are unable to raise capital, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts, engage in one or more potential transactions, or cease our operations entirely. We are continuing to evaluate strategic alternatives and our ability to extend our capital resources. The potential impact and success of our exploration of any strategic alternatives, if available at all, are uncertain and may not be successful.
  • We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.
  • We have no products approved for commercial sale and have not generated any revenue from product sales. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.
  • We will need to obtain substantial additional funding to finance our operations and complete the development and any commercialization of WTX-124, WTX-330, our INDUCER molecules, and any future product candidates. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate one or more of our research and development programs or other operations.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our platform technology or product candidates.
  • We have a term loan facility that requires us to comply with certain operating covenants and places restrictions on our operating and financial flexibility.
  • Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  • Risks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
  • We are early in our development efforts and our current product candidates will require successful completion of preclinical and clinical development before we can seek regulatory approval for any product candidates.
The other 65 risks
  • Our business is highly dependent on the success of our initial INDUKINE and INDUCER molecules, which are in the early stages of development and will require significant additional preclinical and clinical development before we can seek regulatory approval for and launch a product commercially.
  • Our approach to the discovery and development of product candidates based on our PREDATOR platform is unproven, and we do not know whether we will be able to develop any products of commercial value.
  • Manufacturing INDUKINE and INDUCER molecules is subject to risk since they are a novel class of multi-domain biologics that include protease cleavable linkers, and they have never been produced on a commercial scale. We may be unable to manufacture INDUKINE or INDUCER molecules at the scale needed for late-stage clinical development and commercial production on a timely basis or at all, which would adversely affect our ability to conduct clinical trials and seek regulatory approvals or commercialize our programs, which would have an adverse effect on our business.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.
  • Preclinical studies and clinical trials are expensive, time-consuming and difficult to design and implement, and involve uncertain outcomes. Furthermore, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials.
  • We may encounter substantial delays in the commencement or completion, or termination or suspension, of our clinical trials, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
  • If we experience delays or difficulties in the enrollment of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • Our product candidates may cause undesirable or unexpectedly severe side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
  • Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • We are developing WTX-124, and could potentially develop WTX-330 and future product candidates, in combination with third-party drugs, some of which may still be in development, and we will have limited or no control over the safety, supply, regulatory status or regulatory approval of such drugs.
  • We may not be successful in our efforts to identify or discover additional product candidates.
  • We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or following commercial sale, and any product liability insurance we may obtain may not cover all damages from such claims.
  • We have never commercialized a product candidate and we may lack the necessary expertise, personnel and resources to successfully commercialize any products that receive regulatory approval, either on our own or together with collaborators.
  • We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
  • The sizes of the potential markets for our product candidates are difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates.
  • The successful commercialization of our product candidates will depend in part on the extent to which we obtain and maintain favorable coverage, adequate reimbursement levels and pricing policies with third party payors.
  • Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community necessary for commercial success.
  • We expect that WTX-124 and WTX-330, and other product candidates we develop, will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.
  • Risks Related to Our Dependence on Third Parties
  • We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any product candidates.
  • The manufacturing of biologics is complex and we do not have our own clinical manufacturing capabilities. We will rely on third parties to produce preclinical, clinical and commercial supplies of all current and any future product candidates.
  • We have entered into, and may in the future seek to enter into, collaborations or other similar arrangements for our product candidates. If we are unable to enter into such collaborations, or if these collaborations are not successful, our business could be adversely affected.
  • Risks Related to Our Intellectual Property
  • If we are unable to obtain and maintain patent protection for any product candidates we develop or for our PREDATOR platform and other proprietary technologies we may develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize product candidates and technology similar or identical to our product candidates and technology, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.
  • We rely on the Harpoon Agreement for patent rights with respect to our product candidates and may in the future acquire additional third-party intellectual property rights on which we may similarly rely. We face risks with respect to such reliance, including the risk that we could lose these rights that are important to our business if we fail to comply with our obligations under these licenses.
  • If our efforts to protect the proprietary nature of the intellectual property related to our technologies and product candidates are not adequate, we may not be able to compete effectively in our market.
  • Our proprietary position in part depends upon patents that are manufacturing, formulation or method-of-use patents, which may not prevent a competitor or other third party from using the same product candidate for another use.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.
  • We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Issued patents covering our product candidates or technology could be found invalid or unenforceable if challenged in court or the USPTO.
  • Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.
  • If we do not obtain patent term extension and data exclusivity for any of our current or future product candidates, our business may be materially harmed.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected.
  • Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.
  • Risks Related to Regulatory Approval and Marketing of Our Product Candidates and Other Legal Compliance Matters
  • Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to commercialize a product candidate.
  • Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. Any approval we may be granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions and any of our product candidates that may be approved for marketing in a foreign jurisdiction will be subject to risks associated with foreign operations.
  • We may not be able to obtain orphan drug designation or orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing products.
  • Any product candidate for which we obtain marketing approval is subject to ongoing regulation and could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements, when and if any of our product candidates are approved.
  • Any regulatory approval to market our products will be limited by indication. If we fail to comply or are found to be in violation of FDA regulations restricting the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.
  • We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.
  • We may seek PRIME Designation in the EU for one or more of our product candidates, but we might not receive such designations and, even if we do, such designations may not lead to a faster development or regulatory review or approval process.
  • Accelerated approval by the FDA, even if granted for any of our current or future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.
  • We and our contract manufacturers are subject to significant regulation. The manufacturing facilities on which we rely may not continue to meet regulatory requirements, which could materially harm our business.
  • We intend in the future to conduct clinical trials for certain of our product candidates at sites outside the United States. The FDA may not accept data from trials conducted in such locations and the conduct of trials outside the United States could subject us to additional delays and expense.
  • Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for any of our candidate products that do receive marketing approval.
  • Current and future legislative efforts may limit the costs for our products, if and when they are licensed for marketing, and that could materially impact our ability to generate revenues.
  • We may be subject to certain healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, fines, disgorgement, exclusion from participation in government healthcare programs, curtailment or restricting of our operations, and diminished profits and future earnings.
  • Compliance with state, national and international privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to a variety of harms, including significant fines and penalties, litigation and reputational damage, any of which may have a material adverse effect on our business, financial condition or results of operations.
  • We are subject to U.S. and certain foreign export control, import, sanctions, anti-corruption, and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.
  • Changes in and uncertainty surrounding U.S. and international trade policies could have a material adverse impact on our business, financial condition and results of operations.
  • Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
  • Our employees, independent contractors, CROs, consultants, commercial partners, vendors and principal investigators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
  • The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities.
  • Risks Related to Our Business Operations, Employee Matters and Managing Growth
  • Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.
  • We may encounter difficulties in managing the growth of our organization, which could disrupt our operations.
  • Our business could be negatively affected by cyberattacks or a deficiency in our cybersecurity.
  • Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches.
  • Business disruptions and unfavorable economic conditions could seriously harm our business, future revenue and financial condition, and could increase our costs and expenses.

Legal proceedings

We are not currently a party to any material legal proceedings.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54